C HEALTH GP (08225) Successfully Recovers RMB 11.0869 Million from Related Parties as of November 30

Stock News
2025/12/01

C HEALTH GP (08225) announced that, as disclosed in its 2024 Annual Report, the company's total accounts receivable stood at RMB 128 million as of December 31, 2024, with appropriate impairment provisions made in accordance with accounting standards. These receivables primarily arose from the group's ordinary business operations and are common in the industry.

Since the annual report disclosure, the company has actively pursued debt recovery, implementing tailored strategies based on debtor circumstances. Key progress includes:

1. **Recovery from Related Parties** The company strengthened collection efforts through dedicated mechanisms, ongoing communication, and formal notices. As of November 30, 2025, RMB 11.0869 million has been successfully recovered from related parties. For outstanding amounts, arbitration proceedings have been initiated and accepted, with legal follow-ups underway.

2. **Recovery from Non-Related Parties** - **Cooperative Clients**: Through improved engagement and negotiations, the company secured additional repayments totaling RMB 4.4514 million, with repayment plans progressing steadily. - **Challenging Cases**: For long-overdue or financially distressed clients, third-party agencies have been engaged for evaluation and disposal, alongside legal actions to safeguard interests. - **High-Risk Receivables**: The company has pursued all legal measures, including applying to list debtors as失信被执行人 (discredited persons subject to enforcement), while monitoring their assets for actionable opportunities.

3. **Internal Management Enhancements** To improve working capital quality, the company established a "Receivables Management Committee" led by the finance department, strengthening end-to-end controls from credit assessment to payment terms to mitigate new risks.

**Next Steps** The company will continue lawful efforts—such as negotiations, enforcing arbitration awards, and preparing litigation—to maximize recoveries. Progress will be reported to the board periodically, with disclosures made per exchange regulations.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10